Monitor future buyback activity and total program size; assess impact on EPS and capital allocation strategy. Consider potential signal of management confidence, but note this is a routine program execution.
GSK drugs
GSK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 26 $53.94entry
- T+1 · 8mo ago −0.19%α +1.49% · $53.84
- T+5 · 8mo ago +5.10%α +3.46% · $56.69
- T+20 · 7mo ago +0.93%α −9.74% · $54.44
- T+60 · 5mo ago −4.17%α −18.12% · $51.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK plc announced the purchase of 345,000 of its ordinary shares on 25 March 2026 at a volume-weighted average price of 2,033.20 GBp per share, as part of its ongoing buyback program. Since 17 February 2026, the company has bought back 14,856,521 shares. The shares were acquired through BNP Paribas SA and will be held as treasury shares.
Key Facts
- GSK purchased 345,000 ordinary shares on 25 March 2026
- Volume-weighted average price paid: 2,033.20 GBp per share
- Shares were acquired via BNP Paribas SA as part of a non-discretionary buyback program
- Since 17 February 2026, GSK has bought back 14,856,521 shares
- Purchased shares will be held as treasury shares
Financial Impact
Total cost of 345,000 shares at 2,033.20 GBp is approximately £7.01 million (based on GBP/USD exchange rate of 1.28, ~$9.0 million)
Risk Factors
- Buybacks reduce cash reserves and may signal limited growth investment opportunities
- If buybacks continue at elevated pace, could constrain future R&D or M&A capacity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-002780 |
| Document: 0001654954-26-002780-index-headers.html | 0001654954-26-002780 |
| Document: 0001654954-26-002780-index.html | 0001654954-26-002780 |
| Document: 0001654954-26-002780.txt | 0001654954-26-002780 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers